An Expert Overview of Stem Cell Mobilization in Myeloma

News
Video

An expert sat down with CURE® and discussed how stem cells are collected before a patient with myeloma undergoes a stem cell transplant.

A stem cell transplant is one of the most efficient tools to treat multiple myeloma, a cancer that originates in the plasma that builds up within the bone marrow, according to expert Dr. Joseph Mikhael, professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center, and is also the Chief Medical Officer of the International Myeloma Foundation.

“We collect a patient's stem cells and then give them high dose chemotherapy then restore their stem cells to grow a new marrow because that chemotherapy not only affects the myeloma but affects their own inherent marrow. And to do that, we've tried over many, many years different types of therapies for mobilization. Mobilization is the phrase (where we) will encourage those stem cells to leave the bone marrow so that they can circulate in the blood and we can collect them off a machine called an apheresis machine, which functions much like dialysis like machine,” explained Mikhael.

The new advancement of G-CSF (granulocyte-colony stimulating factor), a factor that duplicates the production of white cells, which pushes negative stem cells out of the body. Adding a new agent to G-CSF, Aphexda (motixafortide), makes treatment even more beneficial, as both drugs worked to collect more stem cells in a shorter period of time compared to GC-SF alone.

Transcript:

One of the things that we know is a very important tool in multiple myeloma is a target stem cell transplants, where we collect a patient's stem cells and then give them high-dose chemotherapy then restore their stem cells to grow a new marrow, because that chemotherapy not only affects the myeloma, but affects their own inherent marrow.

And to do that, we've tried over many, many years different types of therapies for mobilization. Mobilization is the phrase, of course, we use to, if you will encourage those stem cells to leave the bone marrow so that they can circulate in the blood and we can collect them off a machine called an apheresis machine, which functions much like dialysis like machine.

Back in the days when I was in training, we did we did harvests by actually doing bone marrows in the operating room on patients directly out of their bone marrow, we almost never do that anymore. Now we can, with the use of novel treatments, mobilize those stem cells as it were out of the bone marrow and into the peripheral blood.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE